Bladen v. C.B. Fleet Holding Co.

487 F. Supp. 2d 759, 2007 U.S. Dist. LEXIS 30894, 2007 WL 1237799
CourtDistrict Court, W.D. Louisiana
DecidedApril 25, 2007
DocketCivil Action 06-0973
StatusPublished
Cited by10 cases

This text of 487 F. Supp. 2d 759 (Bladen v. C.B. Fleet Holding Co.) is published on Counsel Stack Legal Research, covering District Court, W.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bladen v. C.B. Fleet Holding Co., 487 F. Supp. 2d 759, 2007 U.S. Dist. LEXIS 30894, 2007 WL 1237799 (W.D. La. 2007).

Opinion

MEMORANDUM RULING ON MOTION TO DISMISS

DOHERTY, District Judge.

Pending before the Court is a Motion to Dismiss [Doc. 2] under Fed.R.Civ.P. 12(b)(6) filed by the defendants, C.B. Fleet Holding Co. and C.B. Fleet Company, Inc. (collectively, “Fleet”). Fleet seeks dismissal of Counts II (Enrichment without Cause pursuant to La. C.C. Art. 2298), III (Violation of Louisiana Unfair Trade Practices Act (LUTPA) pursuant to La. R.S. 51:4101, et seq.), 1 and IV (Fraud and Deceit) of the plaintiffs’ Complaint. Specifically, Fleet argues plaintiffs, Francis Bladen and Kate Bladen (collectively, “plaintiffs”), are precluded from bringing Counts II, III, and IV because the Louisiana Products Liability Act (LPLA) provides the exclusive remedy for plaintiffs’ complaints.

In response, plaintiffs filed an Opposition to Motion to Dismiss [Doc. 9], in which they agree to voluntarily dismiss counts II (Enrichment without Cause) and IV (Fraud and Deceit) of their complaint; however, plaintiffs oppose the dismissal of Count III (LUTPA violation). Plaintiffs acknowledge the LPLA provides exclusive theories of liability; however, they argue their LUTPA allegations are not barred by the LPLA’s exclusive theories of recovery provision.

As plaintiffs have no opposition to Fleet’s Motion to Dismiss Counts II and IV of plaintiffs’ petition and the Court sees *762 no error in law, the Court GRANTS Fleet’s Motion to Dismiss as to those counts. For the reasons that follow, Fleet’s Motion to Dismiss Count HI of plaintiffs’ petition pursuant to Rule 12(b)(6) is also GRANTED.

FACTS

In their June 9, 2006 petition, Plaintiffs, Francis and Kate Bladen, allege that on or about January 20, 2004, Mr. Francis was given a 1.5 ounce unflavored package of “C.B. Fleet Phosphosoda” (the “product”) at the Veteran’s Administration Medical Center in Alexandria, Louisiana, where he was scheduled to undergo a sigmoidoscopy procedure on January 21, 2004. The product allegedly contained “no product insert” and there were “no warnings regarding kidney damage, kidney or renal failure, or risk to persons” in Mr. Bladen’s age group. At some point after the January 21, 2004 procedure, Mr. Bladen’s laboratory results revealed “elevated creatine levels,” and he was referred by his treating physician to a nephrologist, who, in July 2004, diagnosed Mr. Bladen with “acute renal failure.” Plaintiffs contend Mr. Bladen was a “relatively fit and health[y] man” prior to his use of the product, but has now sustained permanent damage, including renal impairment, following his ingestion of the product. (Complaint ¶¶ VIII-XVI).

Plaintiffs allege in Count I of their petition that Fleet is liable to plaintiffs under the LPLA as a “manufacturer/seller” of the product. Plaintiffs allege the product is unreasonably dangerous in construction and composition and also unreasonably dangerous in design. Plaintiffs further allege the product is unreasonably dangerous because an adequate warning about the product was not provided. Specifically, plaintiffs allege Fleet: (1) did not adequately reflect the symptoms, scope or severity of the possible adverse side effects of the product; (2) did not perform adequate testing that would have demonstrated the product’s harmful side effects; (3) continued to market the product despite the fact Fleet knew its product caused unreasonable, dangerous side effects; (4) failed to include proper warnings regarding all possible adverse side effects; (5) “remained silent” despite its knowledge of public acceptance to Fleet’s “information, misrepresentations, and omissions” regarding the safety of the product and “did so because the prospect of profits outweighed health and safety of ‘consumers,’ ” including Mr. Bladen; (6) recklessly, falsely and deceptively misrepresented or knowingly omitted, suppressed or concealed material facts regarding the safety of the product from the “FDA,” which would never have approved the product “for sale to consumers and no physician would have been able to prescribe” the product; and (7) failed to comply with its post-manufacturing duty to warn when Fleet knew that the product was being “prescribed without warning of the true risks of side effects.” Plaintiffs also contend the product is unreasonably dangerous because it does not conform to Fleet’s implied and express warranties about the product when Fleet knew of the product’s intended use. (Complaint ¶¶ XVII-XXXVI).

In Count III of plaintiffs’ petition, plaintiffs aver Fleet is liable to them under LUTPA. Without identifying any specific dates on which any alleged unfair deceptive trade practices occurred, plaintiffs allege Fleet violated LUTPA by: (1) failing to disclose material information concerning the product, which information was known to Fleet at the time of sale of the product; (2) failing to disclose to the public Fleet’s knowledge of the potential adverse side effects; (3) failing to disclose to government authorities and to the public important scientific information regarding the product; (4) failing to disclose to the public meaningful information regarding proper *763 hydration in connection with the use of the product; (5) failing to provide the public with complete information concerning the potential harmful side effects of the product, including “failure to provide the same warnings Fleet provides to foreign purchasers and consumers;” (6) knowingly malting “false representations as to characteristics, uses, or benefits” of the product; (7) misrepresenting the impact of the product on renal function; (8) misrepresenting the potential adverse side-effects of the product on certain age groups within Fleet’s targeted market; and (9) misrepresenting the dissemination of Fleet’s scientific information. According to plaintiffs, by means of the foregoing “deceptive trade practices,” Fleet “unlawfully acquired money from numerous Louisiana consumers, including plaintiffs.” (Complaint ¶¶ L-LV).

LAW

1. Standard of Review

The test for determining the sufficiency of a complaint under Rule 12(b)(6) was established by the United States Supreme Court: “[A] complaint should not be dismissed for failure to state a claim unless it appears beyond doubt that the plaintiff can prove no set of facts in support of his claim which would entitle him to relief.” Ramming v. U.S., 281 F.3d at 158, 161 (5th Cir.12/19/2001) (citing Conley v. Gibson, 355 U.S. 41, 45-46, 78 S.Ct. 99, 2 L.Ed.2d 80 (1957)). In evaluating a defendant’s motion to dismiss, a court is obligated to construe the plaintiffs complaint “in a light most favorable to the plaintiff, and the allegations contained therein are to be taken as true.” 281 F.3d at 161 (citing Oppenheimer v. Prudential Securities, Inc., 94 F.3d 189, 194(5 Cir.1996)). The court is obligated to examine the complaint to determine whether the allegations provide relief on any possible theory. 281 F.3d at 162 (citing Cinel v. Connick,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
487 F. Supp. 2d 759, 2007 U.S. Dist. LEXIS 30894, 2007 WL 1237799, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bladen-v-cb-fleet-holding-co-lawd-2007.